India, May 9 -- Akero Therapeutics (AKRO) unveiled new data from its Phase 2b SYMMETRY trial highlighting the potential of efruxifermin - EFX to reverse fibrosis in patients with compensated cirrhosis (F4) due to metabolic dysfunction-associated steatohepatitis or MASH.
The results were presented at the EASL Congress 2025 in Amsterdam.
In the presentation, Akero emphasized that cirrhosis caused by MASH has no effective medical treatments besides liver transplant, underscoring the high unmet need. EFX, according to the company, is the first therapy to demonstrate fibrosis reversal in this population, marking a breakthrough that sets it apart from current options.
Lead investigator Dr. Mazen Noureddin stated that without a transplant, MASH...